Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methoprene SCHEMBL28643024 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP3A4TDP1HCAR2 | |
| Methoprene SCHEMBL43694 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP3A4TDP1HCAR2 | |
| Methoprene SCHEMBL1190845 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP3A4TDP1HCAR2 | |
| Methoprene SCHEMBL27840843 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP3A4TDP1HCAR2 | |
| Methoprene SCHEMBL851922 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP3A4TDP1HCAR2 | |
| Methoprene SCHEMBL19795 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP3A4TDP1HCAR2 | |
| Methoprene SCHEMBL11460879 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNACYP3A4TDP1 | |
| SCHEMBL11865825 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP3A4TDP1 | |
| Methoprene SCHEMBL11470834 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP3A4TDP1HCAR2 | |
| SCHEMBL11865831 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970544-B2 | Antibodies | GENMAB A/S (DK) | 2024-04-30 | — | — | US | disclosed |
| EP-4334359-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 AND CD3 | Genmab A/S (DK) | 2024-03-13 | — | — | EP | disclosed |
| CN-117396509-A | Pharmaceutical composition comprising a bispecific antibody binding to B7H4 and CD3 | 健玛保 | 2024-01-12 | — | — | CN | disclosed |
| CN-111670198-B | Binding proteins for the human thrombin receptor PAR4 | 莫纳什大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230257479-A1 | BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-17 | — | — | US | disclosed |
| EP-4121456-A1 | ANTIBODIES BINDING TO B7H4 | Genmab A/S (DK) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298221-A | Antibodies that bind B7H4 | 健玛保 | 2022-11-04 | — | — | CN | disclosed |
| EP-4028424-A1 | BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER | Genmab A/S (DK) | 2022-07-20 | — | — | EP | disclosed |
| US-11261254-B1 | Antibodies | GENMAB A/S (DK) | 2022-03-01 | — | — | US | disclosed |
| US-20220048999-A1 | ANTIBODIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-02-17 | — | — | US | disclosed |
| EP-3233919-A1 | DICAM-SPECIFIC ANTIBODIES AND USES THEREOF | Centre Hospitalier De L'Universite de Montreal (CA) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095046-A1 | DICAM-SPECIFIC ANTIBODIES AND USES THEREOF | VAL-CHUM, LIMITED PARTNERSHIP (CA) | 2016-06-23 | — | — | WO | disclosed |
| US-9221918-B2 | Antigen binding polypeptides | ARGEN-X B.V. (NL) | 2015-12-29 | — | — | US | disclosed |
| US-20150239990-A1 | ANTIGEN BINDING POLYPEPTIDES | argenx BV (BE) | 2015-08-27 | — | — | US | disclosed |
| WO-2013012733-A1 | HETERODIMERIC FC REGIONS, BINDING MOLECULES COMPRISING SAME, AND METHODS RELATING THERETO | BIOGEN IDEC MA INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2001075856-A1 | DNA ANALYSIS SOFTWARE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-10-11 | — | — | WO | disclosed |
| US-6001382-A | COMPRISING COMPLEXES FOR TREATING A POPULATION OF ONE OR MORE AQUATIC ORGANISMS IN A COLUMN OF WATER, THE COMPLEXES COMPRISE AT LEAST ONE SYSTEM WHEREIN THE SYSTEM COMPRISES AT LEAST ONE BIOACTIVE AGENT, A CARRIER, AN ORGANIC PLASTICIZER | LEE COUNTY MOSQUITO CONTROL DISTRICT (US) | 1999-12-14 | — | — | US | disclosed |
| US-5858386-A | CONTROLLED RELEASE OF BIOACTIVE AGENTS ON DRY PRE-FLOODED LAND; WATER SOLUBLE, BIODEGRADABLE COATING OF FATTY ALCOHOLS, FATTY ACIDS, FATTY ESTERS OR PHTHALYL ESTERS; MOSQUITO, WEED CONTROL; NO SUPERABSORBENT POLYMERS | LEE COUNTY MOSQUITO CONTROL DISTRICT (US) | 1999-01-12 | — | — | US | disclosed |
| US-5858384-A | Controlled delivery compositions and processes for treating organisms in a column of water or on land | LEE COUNTY MOSQUITO CONTROL DISTRICT (US) | 1999-01-12 | — | — | US | disclosed |
| US-5698210-A | SUSTAINED RELEASE OF INSECTICIDES, PARASITICIDES, HERBICIDES | LEE COUNTY MOSQUITO CONTROL DISTRICT (US) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239990-A1 | ANTIGEN BINDING POLYPEPTIDES | IGLV6-57, IGSF11, CD74 | ALDH1A1 4137/4885LMNA 4769/4885CYP3A4 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.